GOLDEN, Colo. — January 9, 2026 — PharmaJet®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner Scancell has reported updated Phase 2 clinical data from the SCOPE study in unresectable advanced melanoma. In this study, Scancell’s iSCIB1+ immunotherapy was
View
GOLDEN, Colo. — April 17, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present insights from several DNA Cancer Vaccine partner trials using PharmaJet’s Precision Delivery Systems™ at the World Vaccine Congress 2025 on April 23, 2025
View
GOLDEN, Colo. — November 5, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free technology, today announced their upcoming poster presentation on November 8, 2024 at the Society of Immunotherapy of Cancer (SITC) conference. The poster (#741), entitled Modulating Immune
View
GOLDEN, Colo. — October 17, 2024 — PharmaJet® , a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that they will share their latest research results at the World Vaccine Congress – Europe on October 29, 2024 at 1:40 pm GMT.
View
GOLDEN, Colo. — December 13, 2022 — PharmaJet®, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with
View
GOLDEN, Colo. — March 15, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner Immunomic Therapeutics will be starting a phase 1 clinical study of their plasmid DNA vaccine ITI-3000 in
View
GOLDEN, Colo. — January 8, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that the results of the Invectys Phase I clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system, were recently published. The study entitled A First-in-Human Phase I Study of
View
Load more